Table 1.
Reported sensitivity and specificity of microfluidic-based rapid point-of-care tests for detecting SARS CoV-2 antigen October 2020-March 2021.
| References | SARS CoV-2 Microfluidic Antigen Test | Type of patients | COVID-19 prevalence | RT-PCR concordance | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|---|---|---|---|
| Cento et al., Viruses, 2021 | LumiraDx SARS-CoV-2 Ag Test, UK |
Adults | 36 % | 85.6 % | 85 % | 97 % | 94 % | 92 % |
| Bianco et al., Journal of Clinical Virology, 2021 | LumiraDx SARS-CoV-2 Ag Test, UK |
Adults +pediatric |
33 % | 91.5 % | 90.3 % | 92.1 % | 85 % | 95 % |
| Drain et al., Infectious Diseases and Therapy, 2021 | LumiraDx SARS-CoV-2 Ag Test, UK |
Adults +pediatric |
24 % | NA | 97.6 % | 96.6 % | NA | NA |
| Kohmer et al., Journal of Clinical Medicine, 2021 | LumiraDx SARS-CoV-2 Ag Test, UK |
NA | 74 % | 63 % | 50 % | 100 % | 100 % | 41 % |
| Orsi A et al., Journal Virol Methods, 2021 | FREND COVID-19 Ag assay, South Korea |
NA | 54 % | 96.3 % | 93.3 % | 100 % | 100 % | 92.5 % |
| This work | LumiraDx SARS-CoV-2 Ag Test, UK |
Adults | 25.3 % | 96.9 % | 89.6 % | 99.4 % | 97.9 % | 96.7 % |
NA: Not Available.